Isocombretastatin A4 (BioDeep_00000180142)
Main id: BioDeep_00000000868
human metabolite blood metabolite
代谢物信息卡片
phenol, 2-methoxy-5-((1z)-2-(3,4,5-trimethoxyphenyl)ethenyl)-,1-(dihydrogen phosphate)
化学式: C18H20O5 (316.1311)
中文名称:
谱图信息:
最多检出来源 Homo sapiens(blood) 92.5%
分子结构信息
SMILES: COC1=C(C=C(C=C1)C(=C)C2=CC(=C(C(=C2)OC)OC)OC)O
InChI: InChI=1S/C18H20O5/c1-11(12-6-7-15(20-2)14(19)8-12)13-9-16(21-3)18(23-5)17(10-13)22-4/h6-10,19H,1H2,2-5H3
描述信息
D000970 - Antineoplastic Agents
同义名列表
17 个代谢物同义名
phenol, 2-methoxy-5-((1z)-2-(3,4,5-trimethoxyphenyl)ethenyl)-,1-(dihydrogen phosphate); phenol, 2-methoxy-5-((z)-2-(3,4,5-trimethoxyphenyl)ethenyl)-, dihydrogen phosphate; 2-methoxy-5-((z)-2-(3,4,5-trimethoxyphenyl)vinyl)phenyl dihydrogen phosphate; 1-(3,4,5-trimethoxyphenyl)-2-(3-hydroxy-4-methoxyphenyl)ethene; 2-methoxy-5-[1-(3,4,5-trimethoxyphenyl)ethenyl]phenol; 3,4,5-trimethoxy-3-hydroxy-4-methoxystilbene; combretastatin A-4 disodium phosphate; combretastatin A4 phosphate; deoxycombretastatin A-4; isocombretastatin A-4; Isocombretastatin A4; combretastatin A-4; combretastatin A4; fosbretabulin; CRC 87-09; CRC-98-09; CA4DP
数据库引用编号
7 个数据库交叉引用编号
- PubChem: 24996163
- HMDB: HMDB0253622
- ChEMBL: CHEMBL498271
- chemspider: 24709355
- CAS: 1067880-31-2
- LOTUS: LTS0271753
- wikidata: Q105110565
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
1 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
| 亚细胞结构定位 | 关联基因列表 |
|---|
文献列表
- Hangqi Zhang, Ming Li, Xueming Zhou, Li Tang, Guangying Chen, Yongmin Zhang. Design, synthesis of combretastatin A-4 piperazine derivatives as potential antitumor agents by inhibiting tubulin polymerization and inducing autophagy in HCT116 cells.
European journal of medicinal chemistry.
2024 Jun; 272(?):116497. doi:
10.1016/j.ejmech.2024.116497. [PMID: 38759453] - Qizhen Wu, Qian Wang, Yixuan Wang, Jingqiu Huang, Yalin Fang, Weiyi Wu, Wenying Wu, Fanhong Wu, Xiaodong Yu, Yan Sun. A high-throughput and simultaneous determination of combretastatin A-4 phosphate and its metabolites in human plasma using HPLC-MS/MS: Application to a clinical pharmacokinetic study.
Biomedical chromatography : BMC.
2021 Nov; 35(11):e5204. doi:
10.1002/bmc.5204. [PMID: 34165810] - Antonia Charalambous, Victoria Mico, Laura E McVeigh, Gemma Marston, Nicola Ingram, Milène Volpato, Sally A Peyman, James R McLaughlan, Antonia Wierzbicki, Paul M Loadman, Richard J Bushby, Alexander F Markham, Stephen D Evans, P Louise Coletta. Targeted microbubbles carrying lipid-oil-nanodroplets for ultrasound-triggered delivery of the hydrophobic drug, combretastatin A4.
Nanomedicine : nanotechnology, biology, and medicine.
2021 08; 36(?):102401. doi:
10.1016/j.nano.2021.102401. [PMID: 33894396] - Bonan Zhao, Zhipeng Dong, Weixing Liu, Fangning Lou, Qiyan Wang, Hao Hong, Yue Wang. Co-administration of combretastatin A4 nanoparticles and anti-PD-L1 for synergistic therapy of hepatocellular carcinoma.
Journal of nanobiotechnology.
2021 May; 19(1):124. doi:
10.1186/s12951-021-00865-w. [PMID: 33933077] - Libang Zhang, Dongjian Zhang, Meng Gao, Qiaomei Jin, Cuihua Jiang, Tianze Wu, Yuanbo Feng, Yicheng Ni, Zhiqi Yin, Jian Zhang. Design and Evaluation of Rhein-Based MRI Contrast Agents for Visualization of Tumor Necrosis Induced by Combretastatin A-4 Disodium Phosphate.
Molecular imaging and biology.
2021 04; 23(2):220-229. doi:
10.1007/s11307-020-01551-3. [PMID: 33048270] - Xinxiu Yang, Meng Gao, Mengqi Miao, Cuihua Jiang, Dongjian Zhang, Zhiqi Yin, Yicheng Ni, Jing Chen, Jian Zhang. Combining combretastatin A4 phosphate with ginsenoside Rd synergistically inhibited hepatocellular carcinoma by reducing HIF-1α via PI3K/AKT/mTOR signalling pathway.
The Journal of pharmacy and pharmacology.
2021 Mar; 73(2):263-271. doi:
10.1093/jpp/rgaa006. [PMID: 33793802] - Dinaer Mulatihan, Tao Guo, Yanjun Zhao. Azobenzene Photoswitch for Isomerization-Dependent Cancer Therapy via Azo-Combretastatin A4 and Phototrexate.
Photochemistry and photobiology.
2020 11; 96(6):1163-1168. doi:
10.1111/php.13292. [PMID: 32521572] - Libang Zhang, Lichao Liu, Dongjian Zhang, Qiaomei Jin, Meng Gao, Tianze Wu, Yuanbo Feng, Yicheng Ni, Zhiqi Yin, Jian Zhang. Synthesis and Evaluation of Diindole-Based MRI Contrast Agent for In Vivo Visualization of Necrosis.
Molecular imaging and biology.
2020 06; 22(3):593-601. doi:
10.1007/s11307-019-01399-2. [PMID: 31332630] - Aimi Zhang, Tianze Wu, Li Bian, Panli Li, Qiufang Liu, Dongjian Zhang, Qiaomei Jin, Jian Zhang, Gang Huang, Shaoli Song. Synthesis and Evaluation of Ga-68-Labeled Rhein for Early Assessment of Treatment-Induced Tumor Necrosis.
Molecular imaging and biology.
2020 06; 22(3):515-525. doi:
10.1007/s11307-019-01365-y. [PMID: 31250330] - Thomas Wong, Silpa Narayanan, David P Brown, Zhe-Sheng Chen. Synthesis and Cytotoxicity Studies of Stilbene Long-Chain Fatty Acid Conjugates.
Journal of natural products.
2020 05; 83(5):1563-1570. doi:
10.1021/acs.jnatprod.0c00027. [PMID: 32243160] - Meng Gao, Dongjian Zhang, Nan Yao, Qiaomei Jin, Cuihua Jiang, Jian Zhang, Feng Wang. Enhancing intratumoral biodistribution and antitumor activity of nab-paclitaxel through combination with a vascular disrupting agent, combretastatin A-4-phosphate.
Cancer chemotherapy and pharmacology.
2019 12; 84(6):1187-1194. doi:
10.1007/s00280-019-03953-9. [PMID: 31520101] - Qiang Zeng, Yali Liu, Yonggui Song, Bingwei Feng, Pengfei Xu, Baixi Shan, Zhou Liao, Kuangyi Liu, Youbao Zhong, Lai Chen, Dan Su. A UHPLC-MS/MS method coupled with simple and efficient alkaline hydrolysis for free and total determination of conjugate nanomedicine: Pharmacokinetic and biodistribution study of poly (l-glutamic acid)-graft-methoxy poly (ethylene glycol)/combretastatin A4.
Journal of pharmaceutical and biomedical analysis.
2019 May; 169(?):215-224. doi:
10.1016/j.jpba.2019.03.001. [PMID: 30877933] - Yongwei Gu, Juanjuan Ma, Zhiqin Fu, Youfa Xu, Baoan Gao, Jianzhong Yao, Wei Xu, Kedan Chu, Jianming Chen. Development Of Novel Liposome-Encapsulated Combretastatin A4 Acylated Derivatives: Prodrug Approach For Improving Antitumor Efficacy.
International journal of nanomedicine.
2019; 14(?):8805-8818. doi:
10.2147/ijn.s210938. [PMID: 31806973] - Fredrick O Ojike, Nathalie Lavignac, Maxwell A Casely-Hayford. Synthesis and in Vitro Bioactivity of Polyunsaturated Fatty Acid Conjugates of Combretastatin A-4.
Journal of natural products.
2018 09; 81(9):2101-2105. doi:
10.1021/acs.jnatprod.7b01062. [PMID: 30230828] - E Ragozin, A Hesin, A Bazylevich, H Tuchinsky, A Bovina, T Shekhter Zahavi, M Oron-Herman, G Kostenich, M A Firer, T Rubinek, I Wolf, G Luboshits, M Y Sherman, G Gellerman. New somatostatin-drug conjugates for effective targeting pancreatic cancer.
Bioorganic & medicinal chemistry.
2018 07; 26(13):3825-3836. doi:
10.1016/j.bmc.2018.06.032. [PMID: 30017114] - Dongjian Zhang, Meng Gao, Nan Yao, Cuihua Jiang, Wei Liu, Tiannv Li, Shaoli Song, Dejian Huang, Zhiqi Yin, Yunliang Qiu, Qiaomei Jin. Preclinical Evaluation of Radioiodinated Hoechst 33258 for Early Prediction of Tumor Response to Treatment of Vascular-Disrupting Agents.
Contrast media & molecular imaging.
2018; 2018(?):5237950. doi:
10.1155/2018/5237950. [PMID: 29681781] - Yurun Shen, Liping Wu, Liyan Qiu. Water-Soluble Combretastatin A4 Phosphate Orally Delivered via Composite Nanoparticles With Improved Inhibition Effect Toward S180 Tumors.
Journal of pharmaceutical sciences.
2017 10; 106(10):3076-3083. doi:
10.1016/j.xphs.2017.05.031. [PMID: 28619603] - Hongsheng Wang, Wen Li, Jing Xu, Tao Zhang, Dongqing Zuo, Zifei Zhou, Binhui Lin, Gangyang Wang, Zhuoying Wang, Wei Sun, Mengxiong Sun, Shimin Chang, Zhengdong Cai, Yingqi Hua. NDRG1 inhibition sensitizes osteosarcoma cells to combretastatin A-4 through targeting autophagy.
Cell death & disease.
2017 09; 8(9):e3048. doi:
10.1038/cddis.2017.438. [PMID: 28906492] - Victoria Mico, Antonia Charalambous, Sally A Peyman, Radwa H Abou-Saleh, Alexander F Markham, P Louise Coletta, Stephen D Evans. Evaluation of lipid-stabilised tripropionin nanodroplets as a delivery route for combretastatin A4.
International journal of pharmaceutics.
2017 Jun; 526(1-2):547-555. doi:
10.1016/j.ijpharm.2017.05.009. [PMID: 28495582] - Tianzhou Liu, Dawei Zhang, Wantong Song, Zhaohui Tang, Jiaming Zhu, Zhiming Ma, Xudong Wang, Xuesi Chen, Ti Tong. A poly(l-glutamic acid)-combretastatin A4 conjugate for solid tumor therapy: Markedly improved therapeutic efficiency through its low tissue penetration in solid tumor.
Acta biomaterialia.
2017 04; 53(?):179-189. doi:
10.1016/j.actbio.2017.02.001. [PMID: 28167300] - Meng Gao, Dongjian Zhang, Qiaomei Jin, Cuihua Jiang, Cong Wang, Jindian Li, Fei Peng, Dejian Huang, Jian Zhang, Shaoli Song. Combretastatin-A4 phosphate improves the distribution and antitumor efficacy of albumin-bound paclitaxel in W256 breast carcinoma model.
Oncotarget.
2016 09; 7(36):58133-58141. doi:
10.18632/oncotarget.11249. [PMID: 27531898] - Alina Ghinet, Iuliana-Monica Moise, Benoît Rigo, Germain Homerin, Amaury Farce, Joëlle Dubois, Elena Bîcu. Studies on phenothiazines: New microtubule-interacting compounds with phenothiazine A-ring as potent antineoplastic agents.
Bioorganic & medicinal chemistry.
2016 05; 24(10):2307-17. doi:
10.1016/j.bmc.2016.04.001. [PMID: 27073050] - Florence Colliez, Anne-Catherine Fruytier, Julie Magat, Marie-Aline Neveu, Patrice D Cani, Bernard Gallez, Bénédicte F Jordan. Monitoring Combretastatin A4-induced tumor hypoxia and hemodynamic changes using endogenous MR contrast and DCE-MRI.
Magnetic resonance in medicine.
2016 Feb; 75(2):866-72. doi:
10.1002/mrm.25642. [PMID: 25765253] - Nan Yao, Ke Ren, Cuihua Jiang, Meng Gao, Dejian Huang, Xiao Lu, Bin Lou, Fei Peng, Aizhen Yang, Xiaoning Wang, Yicheng Ni, Jian Zhang. Combretastatin A4 phosphate treatment induces vasculogenic mimicry formation of W256 breast carcinoma tumor in vitro and in vivo.
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.
2015 Nov; 36(11):8499-510. doi:
10.1007/s13277-015-3508-x. [PMID: 26026583] - Qingen Ke, Mohammed A Samad, Soochan Bae, David J Chaplin, Peter M Kang. Exaggerated hypertensive response to combretastatin A-4 phosphate in hypertensive rats: Effective pharmacological inhibition by diltiazem.
Vascular pharmacology.
2015 Nov; 74(?):73-79. doi:
10.1016/j.vph.2015.05.004. [PMID: 25989107] - Xuejiao Liu, Cuihua Jiang, Dongjian Zhang, Meng Gao, Fei Peng, Dejian Huang, Ziping Sun, Yicheng Ni, Jian Zhang, Zhiqi Yin. Tumor necrosis targeted radiotherapy of non-small cell lung cancer using radioiodinated protohypericin in a mouse model.
Oncotarget.
2015 Sep; 6(28):26400-10. doi:
10.18632/oncotarget.4568. [PMID: 26305548] - Meng Gao, Nan Yao, Dejian Huang, Cuihua Jiang, Yuanbo Feng, Yue Li, Bin Lou, Fei Peng, Ziping Sun, Yicheng Ni, Jian Zhang. Trapping effect on a small molecular drug with vascular-disrupting agent CA4P in rodent H22 hepatic tumor model: in vivo magnetic resonance imaging and postmortem inductively coupled plasma atomic emission spectroscopy.
Journal of drug targeting.
2015 Jun; 23(5):436-43. doi:
10.3109/1061186x.2014.1002789. [PMID: 25582132] - Rajesh R Wakaskar, Sai Praneeth R Bathena, Shailendra B Tallapaka, Vishakha V Ambardekar, Nagsen Gautam, Rhishikesh Thakare, Samantha M Simet, Stephen M Curran, Rakesh K Singh, Yuxiang Dong, Joseph A Vetro. Peripherally cross-linking the shell of core-shell polymer micelles decreases premature release of physically loaded combretastatin A4 in whole blood and increases its mean residence time and subsequent potency against primary murine breast tumors after IV administration.
Pharmaceutical research.
2015 Mar; 32(3):1028-44. doi:
10.1007/s11095-014-1515-z. [PMID: 25223962] - Nan Yao, Meng Gao, Ke Ren, Xiao Jiang, Yue Li, Cuihua Jiang, Dejian Huang, Wei Liu, Xiaoning Wang, Zhijun Fang, Ziping Sun, Jian Zhang, Yicheng Ni. PD806: a novel oral vascular disrupting agent shows antitumor and antivascular effects in vitro and in vivo.
Anti-cancer drugs.
2015 Feb; 26(2):148-59. doi:
10.1097/cad.0000000000000168. [PMID: 25222529] - Yun Ji, Cuihua Jiang, Xueli Zhang, Wei Liu, Meng Gao, Yue Li, Junhu Wang, Qingqing Wang, Ziping Sun, Xiao Jiang, Nan Yao, Xiaoning Wang, Zhijun Fang, Zhiqi Yin, Yicheng Ni, Jian Zhang. Necrosis targeted combinational theragnostic approach using radioiodinated Sennidin A in rodent tumor models.
Oncotarget.
2014 May; 5(10):2934-46. doi:
10.18632/oncotarget.1728. [PMID: 24931286] - Yun-Wei Shi, Cai-Ping Wang, Lei Liu, Yang-Liu Liu, Xing Wang, Ye Hong, Zhen Li, Ling-Dong Kong. Antihyperuricemic and nephroprotective effects of resveratrol and its analogues in hyperuricemic mice.
Molecular nutrition & food research.
2012 Sep; 56(9):1433-44. doi:
10.1002/mnfr.201100828. [PMID: 22865646] - Roger H Bisby, Stanley W Botchway, John A Hadfield, Alan T McGown, Anthony W Parker, Kathrin M Scherer. Fluorescence lifetime imaging of E-combretastatin uptake and distribution in live mammalian cells.
European journal of cancer (Oxford, England : 1990).
2012 Aug; 48(12):1896-903. doi:
10.1016/j.ejca.2011.11.025. [PMID: 22209092] - Xiao-Ping Xu, Xiao-Dong Wu, Gui-Lun Liang, Wen-Sheng Huang, Li Wang, Hai-Ying Jing, Shi-Long Zhong. Pharmacokinetics, excretion, and distribution of combretastatin A4 phosphate in rats.
Die Pharmazie.
2012 Jun; 67(6):529-33. doi:
NULL. [PMID: 22822542] - Xuexin He, Su Li, He Huang, Zhiming Li, Likun Chen, Sheng Ye, Jiajia Huang, Jing Zhan, Tongyu Lin. A pharmacokinetic and safety study of single dose intravenous combretastatin A4 phosphate in Chinese patients with refractory solid tumours.
British journal of clinical pharmacology.
2011 Jun; 71(6):860-70. doi:
10.1111/j.1365-2125.2011.03928.x. [PMID: 21276042] - Zhe Wang, Paul C Ho. Self-assembled core-shell vascular-targeted nanocapsules for temporal antivasculature and anticancer activities.
Small (Weinheim an der Bergstrasse, Germany).
2010 Nov; 6(22):2576-83. doi:
10.1002/smll.201001122. [PMID: 20976704] - Xiaojing Wang, Zhihang Chen, Jinjing Che, Qingfang Meng, Chengqi Shan, Yunan Hou, Xiaolei Liu, Yifeng Chai, Yuanguo Cheng. Development of a rapid and sensitive LC-MS/MS assay for the determination of combretastatin A4 phosphate, combretastatin A4 and combretastatin A4 glucuronide in beagle dog plasma and its application to a pharmacokinetic study.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2009 Nov; 877(30):3813-21. doi:
10.1016/j.jchromb.2009.09.027. [PMID: 19822461] - Yuval Shaked, Terence Tang, Jill Woloszynek, Laura G Daenen, Shan Man, Ping Xu, Shi-Rong Cai, Jeffrey M Arbeit, Emile E Voest, David J Chaplin, Jon Smythe, Adrian Harris, Paul Nathan, Ian Judson, Gordon Rustin, Francesco Bertolini, Daniel C Link, Robert S Kerbel. Contribution of granulocyte colony-stimulating factor to the acute mobilization of endothelial precursor cells by vascular disrupting agents.
Cancer research.
2009 Oct; 69(19):7524-8. doi:
10.1158/0008-5472.can-09-0381. [PMID: 19738066] - Colin J Mooney, Govardhanan Nagaiah, Pingfu Fu, Jay K Wasman, Matthew M Cooney, Panos S Savvides, Joseph A Bokar, Afshin Dowlati, Ding Wang, Sanjiv S Agarwala, Susan M Flick, Paul H Hartman, Jose D Ortiz, Pierre N Lavertu, Scot C Remick. A phase II trial of fosbretabulin in advanced anaplastic thyroid carcinoma and correlation of baseline serum-soluble intracellular adhesion molecule-1 with outcome.
Thyroid : official journal of the American Thyroid Association.
2009 Mar; 19(3):233-40. doi:
10.1089/thy.2008.0321. [PMID: 19265494] - S Aprile, E Del Grosso, G Grosa. In vitro and in vivo phase II metabolism of combretastatin A-4: evidence for the formation of a sulphate conjugate metabolite.
Xenobiotica; the fate of foreign compounds in biological systems.
2009 Feb; 39(2):148-61. doi:
10.1080/00498250802566976. [PMID: 19255941] - Dietmar W Siemann, Wenyin Shi. Dual targeting of tumor vasculature: combining Avastin and vascular disrupting agents (CA4P or OXi4503).
Anticancer research.
2008 Jul; 28(4B):2027-31. doi:
NULL. [PMID: 18751370] - Thomas Nielsen, Kim Mouridsen, Ross J Maxwell, Hans Stødkilde-Jørgensen, Leif Østergaard, Michael R Horsman. Segmentation of dynamic contrast enhanced magnetic resonance imaging data.
Acta oncologica (Stockholm, Sweden).
2008; 47(7):1265-70. doi:
10.1080/02841860802277489. [PMID: 18661437] - Beth A Salmon, Howard W Salmon, Dietmar W Siemann. Monitoring the treatment efficacy of the vascular disrupting agent CA4P.
European journal of cancer (Oxford, England : 1990).
2007 Jul; 43(10):1622-9. doi:
10.1016/j.ejca.2007.03.018. [PMID: 17451938] - Howard W Salmon, Christopher Mladinich, Dietmar W Siemann. Evaluations of vascular disrupting agents CA4P and OXi4503 in renal cell carcinoma (Caki-1) using a silicon based microvascular casting technique.
European journal of cancer (Oxford, England : 1990).
2006 Nov; 42(17):3073-8. doi:
10.1016/j.ejca.2006.06.016. [PMID: 16956760] - Ramakrishna Nallamothu, George C Wood, Mohammad F Kiani, Bob M Moore, Frank P Horton, Laura A Thoma. A targeted liposome delivery system for combretastatin A4: formulation optimization through drug loading and in vitro release studies.
PDA journal of pharmaceutical science and technology.
2006 May; 60(3):144-55. doi:
". [PMID: 17089683] - Ramakrishna Nallamothu, George C Wood, Christopher B Pattillo, Robert C Scott, Mohammad F Kiani, Bob M Moore, Laura A Thoma. A tumor vasculature targeted liposome delivery system for combretastatin A4: design, characterization, and in vitro evaluation.
AAPS PharmSciTech.
2006 Apr; 7(2):E32. doi:
10.1208/pt070232. [PMID: 16796350] - Vandana Srivastava, Arvind Singh Negi, J K Kumar, M M Gupta, Suman P S Khanuja. Plant-based anticancer molecules: a chemical and biological profile of some important leads.
Bioorganic & medicinal chemistry.
2005 Nov; 13(21):5892-908. doi:
10.1016/j.bmc.2005.05.066. [PMID: 16129603] - Ian G Kirwan, Paul M Loadman, David J Swaine, D Alan Anthoney, George R Pettit, John W Lippert, Steve D Shnyder, Patricia A Cooper, Mike C Bibby. Comparative preclinical pharmacokinetic and metabolic studies of the combretastatin prodrugs combretastatin A4 phosphate and A1 phosphate.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2004 Feb; 10(4):1446-53. doi:
10.1158/1078-0432.ccr-0518-03. [PMID: 14977848] - Philip E Thorpe. Vascular targeting agents as cancer therapeutics.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2004 Jan; 10(2):415-27. doi:
10.1158/1078-0432.ccr-0642-03. [PMID: 14760060] - James P Stevenson, Mark Rosen, Weijing Sun, Maryann Gallagher, Daniel G Haller, David Vaughn, Bruce Giantonio, Ross Zimmer, William P Petros, Michael Stratford, David Chaplin, Scott L Young, Mitchell Schnall, Peter J O'Dwyer. Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2003 Dec; 21(23):4428-38. doi:
10.1200/jco.2003.12.986. [PMID: 14645433] - Helen L Anderson, Jeffrey T Yap, Mathew P Miller, Adele Robbins, Terry Jones, Patricia M Price. Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A4 phosphate.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2003 Aug; 21(15):2823-30. doi:
10.1200/jco.2003.05.186. [PMID: 12807935] - Susan M Galbraith, Ross J Maxwell, Martin A Lodge, Gillian M Tozer, John Wilson, N Jane Taylor, J James Stirling, Luiza Sena, Anwar R Padhani, Gordon J S Rustin. Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2003 Aug; 21(15):2831-42. doi:
10.1200/jco.2003.05.187. [PMID: 12807936] - S E Holwell, P A Cooper, M J Thompson, G R Pettit, L W Lippert, S W Martin, M C Bibby. Anti-tumor and anti-vascular effects of the novel tubulin-binding agent combretastatin A-1 phosphate.
Anticancer research.
2002 Nov; 22(6C):3933-40. doi:
". [PMID: 12553015] - Vivien E Prise, Davina J Honess, Michael R L Stratford, John Wilson, Gillian M Tozer. The vascular response of tumor and normal tissues in the rat to the vascular targeting agent, combretastatin A-4-phosphate, at clinically relevant doses.
International journal of oncology.
2002 Oct; 21(4):717-26. doi:
10.3892/ijo.21.4.717. [PMID: 12239609] - Afshin Dowlati, Kelly Robertson, Matthew Cooney, William P Petros, Michael Stratford, John Jesberger, Niusha Rafie, Beth Overmoyer, Vinit Makkar, Bruce Stambler, Anne Taylor, John Waas, Jonathan S Lewin, Keith R McCrae, Scot C Remick. A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer.
Cancer research.
2002 Jun; 62(12):3408-16. doi:
NULL. [PMID: 12067983] - R Murata, J Overgaard, M R Horsman. Comparative effects of combretastatin A-4 disodium phosphate and 5,6-dimethylxanthenone-4-acetic acid on blood perfusion in a murine tumour and normal tissues.
International journal of radiation biology.
2001 Feb; 77(2):195-204. doi:
10.1080/09553000010007695. [PMID: 11236926] - K Hori, S Saito, Y Nihei, M Suzuki, Y Sato. Antitumor effects due to irreversible stoppage of tumor tissue blood flow: evaluation of a novel combretastatin A-4 derivative, AC7700.
Japanese journal of cancer research : Gann.
1999 Sep; 90(9):1026-38. doi:
10.1111/j.1349-7006.1999.tb00851.x. [PMID: 10551334] - G M Tozer, V E Prise, J Wilson, R J Locke, B Vojnovic, M R Stratford, M F Dennis, D J Chaplin. Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues.
Cancer research.
1999 Apr; 59(7):1626-34. doi:
. [PMID: 10197639] - M R Stratford, M F Dennis. Determination of combretastatin A-4 and its phosphate ester pro-drug in plasma by high-performance liquid chromatography.
Journal of chromatography. B, Biomedical sciences and applications.
1999 Jan; 721(1):77-85. doi:
10.1016/s0378-4347(98)00458-7. [PMID: 10027639] - R T Dorr, K Dvorakova, K Snead, D S Alberts, S E Salmon, G R Pettit. Antitumor activity of combretastatin-A4 phosphate, a natural product tubulin inhibitor.
Investigational new drugs.
1996; 14(2):131-7. doi:
10.1007/bf00210783. [PMID: 8913833] - G R Pettit, C Temple, V L Narayanan, R Varma, M J Simpson, M R Boyd, G A Rener, N Bansal. Antineoplastic agents 322. synthesis of combretastatin A-4 prodrugs.
Anti-cancer drug design.
1995 Jun; 10(4):299-309. doi:
". [PMID: 7786396] - C M Lin, H H Ho, G R Pettit, E Hamel. Antimitotic natural products combretastatin A-4 and combretastatin A-2: studies on the mechanism of their inhibition of the binding of colchicine to tubulin.
Biochemistry.
1989 Aug; 28(17):6984-91. doi:
10.1021/bi00443a031. [PMID: 2819042] - G R Pettit, S B Singh, E Hamel, C M Lin, D S Alberts, D Garcia-Kendall. Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4.
Experientia.
1989 Feb; 45(2):209-11. doi:
10.1007/bf01954881. [PMID: 2920809]
